PHARMACOKINETICS AND TISSUE PENETRATION OF RUFLOXACIN, A LONG-ACTING QUINOLONE ANTIMICROBIAL AGENT

被引:31
|
作者
WISE, R [1 ]
JOHNSON, J [1 ]
OSULLIVAN, N [1 ]
ANDREWS, JM [1 ]
IMBIMBO, BP [1 ]
机构
[1] MEDIOLANUM FARMACEUT,MILAN,ITALY
关键词
D O I
10.1093/jac/28.6.905
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The pharmacokinetics of rufloxacin after a single 400 mg oral dose were studied in eight volunteers, measuring plasma, inflammatory fluid and urine concentrations. Mean peak plasma concentrations of 4-4 mgL were achieved at a mean time of 1-9 h after administration. The mean plasma elimination half-life was 28-2 h. Mean peak levels in inflammatory fluid reached 3-2 mgL after 3-5 h, and 30-7 of the dose was eliminated in urine by 96 h. The apparent mean volume of distribution of rufloxacin, at steady state, was 109-5 L. The mean percentage penetration of rufloxacin into the inflammatory exudate, as measured by ratios of AUQ JO h was 90. © 1991 by The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:905 / 909
页数:5
相关论文
共 50 条
  • [31] New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides
    Tran, Truc T.
    Villegas, Sara Gomez
    Aitken, Samuel L.
    Butler-Wu, Susan M.
    Soriano, Alex
    Werth, Brian J.
    Munita, Jose M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (06)
  • [32] New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides
    Siciliano, Valentina
    Sangiorgi, Flavio
    Del Vecchio, Pierluigi
    Vahedi, Layla
    Gross, Maya Manuela
    Saviano, Angela
    Ojetti, Veronica
    PATHOGENS, 2024, 13 (03):
  • [33] PEGylated recombinant human interferon-ω as a long-acting antiviral agent: Structure, antiviral activity and pharmacokinetics
    Yu, Weili
    Yu, Changming
    Wu, Ling
    Fang, Ting
    Qiu, Rui
    Zhang, Jinlong
    Yu, Ting
    Fu, Ling
    Chen, Wei
    Hu, Tao
    ANTIVIRAL RESEARCH, 2014, 108 : 142 - 147
  • [34] Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects
    Meyerhoff, C
    Dilger, C
    Yoon, SJ
    Chung, YH
    Lee, DK
    Lee, CW
    Ryu, JM
    Choi, MS
    Pabst, G
    Reh, C
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 42 (03) : 349 - 361
  • [35] THE PHARMACOLOGICAL PROPERTIES OF LAUDOLISSIN - A LONG-ACTING CURARIZING AGENT
    COLLIER, HOJ
    MACAULEY, B
    BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1952, 7 (03): : 398 - 408
  • [36] TREATMENT OF HYPERTENSION WITH CHLORTHALIDONE A LONG-ACTING DIURETIC AGENT
    HOWARD, BE
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1965, 7 (05): : 304 - &
  • [37] HL 752: A potent and long-acting antispasmodic agent
    BalTembe, S
    Bhedi, DN
    Mishra, AK
    Rajagopalan, R
    Ghate, AV
    Subbarayan, P
    Punekar, NS
    Kulkarni, AV
    BIOORGANIC & MEDICINAL CHEMISTRY, 1997, 5 (07) : 1381 - 1387
  • [38] MIDODRINE, A LONG-ACTING ALPHA - ADRENERGIC STIMULATING AGENT
    PITTNER, H
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1975, 287 : R22 - R22
  • [39] CLINICAL PHARMACOKINETICS AND PHARMACOLOGICAL ACTIONS OF A LONG-ACTING FORMULATION OF PROPRANOLOL
    OHASHI, K
    EBIHARA, A
    KONDO, K
    USAMI, M
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1984, 34-1 (04): : 507 - 512
  • [40] Pharmacokinetics of Long-Acting Methylphenidate: Formulation Differences, Bioequivalence, Interchangeability
    Mostafa Moharram
    Tony Kiang
    European Journal of Drug Metabolism and Pharmacokinetics, 2024, 49 : 149 - 170